Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.61 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968386 | 0.83 | ESR2 (0.47) | ESR1ESR2ERN1FFAR1PPARD | |
| SCHEMBL12396814 | 0.82 | ESR1 (0.63) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL15968808 | 0.81 | ESR1 (0.60) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL15968518 | 0.79 | FFAR1 (0.42) | ERN1FFAR1PPARDPPARAVSIR | |
| SCHEMBL15968145 | 0.79 | MAPT (0.44) | FFAR1PPARDPPARA | |
| SCHEMBL15968598 | 0.78 | ACACB (0.48) | FFAR1PPARDPPARAVSIR | |
| SCHEMBL1378406 | 0.77 | ESR2 (1.00) | ESR1ESR2NPC1RAB9A | |
| SCHEMBL21162496 | 0.76 | ERN1 (0.59) | ERN1FFAR1PPARD | |
| SCHEMBL1128800 | 0.76 | S1PR5 (0.52) | ERN1NPC1 | |
| SCHEMBL8034090 | 0.75 | ESR1 (0.81) | ESR1ESR2APPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ESR1 2402/4885ESR2 2876/4885ERN1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.